Alpa Laboratories Ltd.
ALPANSEHealthcarePharmaceuticals & DrugsSmall Cap
₹68.11
▲ 0.37%
loading…
55
Composite
Alpa Laboratories, incorporated in 1988, is engaged in the business of manufacturing pharmaceutical products. In 1967, the company started its journey as a partnership concern with Purushottam R Patel, M S Chawla and Pravin C Shah as the founding partners. Later on March 18, 1988 the company became a private limited company and a decade later it became a public limited enterprise.
Q-DITS fundamental score
55Composite
Growth
30
Profitability
54
Valuation
76
Quality
72
Solvency
70
Earnings
30
Key metrics
MCap
₹143 Cr
TTM PE
9.5x
Industry PE
38.2x
TTM EPS
₹7.13
Book Value
₹88.53
Face Value
₹10
Div Yield
0%
PEG
1.61x
PB
1.3x
ROE
12.1%
ROCE
15.8%
EBITDA mgn
25%
D/E
0
Int. Cover
111.7x
Curr. Ratio
4.12x
EPS
₹9.27
Growth — CAGR across horizons
| Metric | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| Net Sales | -5.9% | 4.6% | 1.6% | 7% |
| EBITDA | -30.8% | -24.2% | -15.6% | -4.7% |
| Net Profit | -23% | 5.9% | 15.7% | 9% |
Score snapshot
Piotroski
6/9
Altman Z
2.17
Quality
72.4
Growth
29.8
Valuation
76
Earn. Qual
29.8
PEAD
-2
SURGE
-2
Loading price data…
Loading delivery data…
Revenue, profitability & returns
Revenue & Net Profit (₹ Cr)
RevenueNet Profit
Margins (%)
EBITDA%PAT%
Return ratios (%)
ROEROCEROA
Annual financials — last 10 years
Tap a row to expand the full chart
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 54 | 63 | 63 | 78 | 86 | 98 | 112 | 93 | 109 | 112 | |
| ›EBITDACr | 12 | 10 | 9 | 6 | 6 | 12 | 21 | 17 | 23 | 28 | |
| ›EBITDA margin | 20.9% | 19.3% | 14% | 8.3% | 7.3% | 12.4% | 19.1% | 18.8% | 21.2% | 25% | |
| ›Net profitCr | 7 | 3 | 3 | 1 | 2 | 7 | 14 | 13 | 17 | 20 | |
| ›PAT margin | 11.9% | 4% | 4.5% | 1.3% | 2.2% | 7.4% | 12.6% | 13.5% | 15.4% | 17.3% | |
| ›EPS₹ | ₹3.25 | ₹1.2 | ₹1.33 | ₹0.48 | ₹0.88 | ₹3.44 | ₹6.7 | ₹5.98 | ₹7.97 | ₹9.27 | |
| ›Revenue growth | -6.6% | 18.4% | -1% | 24.1% | 10.2% | 13.5% | 15.1% | -17.2% | 17% | 3.4% | |
| ›PAT growth | 589.8% | -63.2% | 11.3% | -64% | 83.2% | 291% | 94.4% | -10.7% | 33.3% | 16.3% | |
| ›ROE | 7.6% | 2.7% | 2.9% | 1% | 1.9% | 7% | 12.3% | 9.8% | 11.7% | 12.1% | |
| ›ROCE | 9.6% | 6.6% | 5.5% | 3.3% | 3.1% | 10.4% | 16.8% | 12.2% | 14.3% | 15.8% | |
| ›ROA | 5% | 1.9% | 2.3% | 0.8% | 1.5% | 5.6% | 9.5% | 7.8% | 9.6% | 9.6% | |
| ›P/E | 11.7x | 33.7x | 29.2x | 55.1x | 16x | 10.5x | 10.4x | 9x | 10.5x | 11.2x | |
| ›P/B | 0.9x | 0.9x | 0.8x | 0.6x | 0.3x | 0.7x | 1.2x | 0.8x | 1.2x | 1.3x | |
| ›D/E | 0.3 | 0.1 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| ›Current ratio | 2.3x | 3.5x | 4.2x | 4.2x | 4.6x | 3.7x | 4.8x | 5x | 5.7x | 4.1x | |
| ›Interest cover | 7.7x | 4.3x | 5.3x | 5.8x | 15.8x | 139.5x | 90.3x | 72.1x | 58.6x | 111.7x |
Quarterly results
Tap a row to expand the full chart
| Metric | Trend | 2023-12 | 2024-03 | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 27 | 24 | 21 | 25 | 26 | 40 | 19 | 26 | 29 | 31 | |
| ›Rev growth YoY | -0% | -19% | 0% | -23% | -4.2% | 69.1% | -10.9% | 5.3% | 11.1% | -21.4% | |
| ›EBITDACr | 2 | 4 | 1 | 3 | 1 | 0 | 0 | -2 | 2 | 4 | |
| ›EBITDA margin | 8.9% | 14.9% | 2.5% | 13.3% | 2.8% | 0.5% | 2.2% | -8.5% | 5.2% | 11.5% | |
| ›Net profitCr | 5 | 4 | 5 | 8 | 9 | -2 | 12 | 0 | 2 | 1 | |
| ›PAT growth YoY | -11.9% | -23.6% | -9.5% | 32.7% | 97.4% | -159.8% | 130.9% | -98.6% | -78.6% | 165.1% | |
| ›EPS₹ | ₹2.14 | ₹1.69 | ₹2.42 | ₹3.65 | ₹4.23 | ₹-1.01 | ₹5.59 | ₹0.05 | ₹0.9 | ₹0.66 |
Balance sheet — last 10 years (₹ Cr)
Tap a row to expand the full chart
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›Shareholders' equityCr | 95 | 98 | 98 | 100 | 108 | 122 | 135 | 152 | 171 | 186 | |
| ›ReservesCr | 74 | 77 | 77 | 79 | 87 | 101 | 114 | 131 | 150 | 165 | |
| ›Total borrowingsCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| ›InvestmentsCr | 13 | 31 | 49 | 57 | 51 | 77 | 83 | 101 | 120 | 0 | |
| ›Total assetsCr | 96 | 98 | 99 | 101 | 108 | 124 | 135 | 152 | 171 | 242 | |
| ›Current assetsCr | 105 | 98 | 94 | 95 | 121 | 138 | 149 | 161 | 192 | 211 | |
| ›Current liabilitiesCr | 30 | 23 | 22 | 21 | 33 | 29 | 30 | 28 | 47 | 53 | |
| ›Trade payablesCr | 14 | 13 | 13 | 14 | 25 | 15 | 15 | 12 | 19 | 18 | |
| ›Gross blockCr | 36 | 38 | 39 | 40 | 31 | 34 | 33 | 40 | 51 | 20 |
Cash flow statement (₹ Cr)
Tap a row to expand the full chart
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›Operating CF (CFO)Cr | 17 | -13 | -1 | 18 | -2 | 10 | 9 | 4 | 18 | 10 | |
| ›Investing CF (CFI)Cr | -2 | -11 | -15 | -11 | 6 | -16 | 2 | -13 | -12 | -12 | |
| ›Financing CF (CFF)Cr | -15 | 9 | -5 | -1 | 0 | 5 | -4 | 3 | -5 | 2 | |
| ›Net cash changeCr | 0 | -15 | -20 | 5 | 4 | -0 | 7 | -7 | 1 | 1 | |
| ›Closing cashCr | 37 | 21 | 1 | 6 | 11 | 2 | 9 | 3 | 4 | 4 |
Cash flow components
CFO · CFI · CFF (₹ Cr)
CFOCFICFF
Q-DITS scorecard
Composite score
55
Quality (25%)72.4
Growth (25%)29.8
Valuation (20%)76
Piotroski (15%)67
Earnings Quality (10%)29.8
Momentum (5%)—
Weighted blend, rescaled to the components available for this stock.
Piotroski F-Score
6/9
✓ROA positiveROA 9.63%
✓CFO positiveCFO ₹9.95 Cr
✓ROA improving9.6% → 9.63%
✗CFO > PAT (low accruals)CFO 9.95 vs PAT 19.5
✓Leverage decreasedD/E 0.03 → 0.0
✗Liquidity improvedCR 5.74 → 4.12
✓No share dilutionEPS 7.97 → 9.27
✓Margin improvedEBITDA mgn 21.15% → 24.99%
✗Asset turnover upAsset TO 0.62 → 0.56
Altman Z-Scoregrey
2.17
X1
0.654
X2
0.682
X3
0.107
X4
0.769
X5
0.464
>2.9 safe · 1.23–2.9 grey · <1.23 distress
Quality
72.4/100
ROE
12.1%
ROCE
15.8%
Margin
17.3%
Debt
0
Int. cover
111.7x
Growth
29.8/100
Revenue 3Y
4.6%
Profit 3Y
5.9%
EPS
16.3%
Valuation
76/100
PE
11.2x
PB
1.3x
EV/EBITDA
7.7x
vs universe median: PE 25.6x · PB 2.81x · EV 13.41x
Earnings quality
29.8/100
CFO₹10 Cr
PAT₹20 Cr
Accrual ratio0.039
CFO/PAT0.51x
PEAD · SURGE
-2 / -2
Revenue SUE-0.96
EPS SUE-0.78
Latest quarter2026-03
Rev growth YoY-21.4%
Documents & filings
Loading documents…
Peer comparison
| Company | MCap (Cr) | Revenue | PAT | PE | PB | ROE% | ROCE% | D/E |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,40,794 | 58,462 | 11,565 | 38.4x | 5.3x | 16.2 | 19.9 | 0.03 |
| Divi's Laboratories Ltd. | 1,78,956 | 10,560 | 2,568 | 69.7x | 10.7x | 15.4 | 20.5 | 0 |
| Torrent Pharmaceuticals Ltd. | 1,49,820 | 13,980 | 2,138 | 69.3x | 17.9x | 26.8 | 19.3 | 1.76 |
| Cipla Ltd. | 1,09,370 | 28,163 | 3,870 | 28.2x | 3.2x | 11.8 | 16 | 0.01 |
| Lupin Ltd. | 1,07,537 | 27,958 | 5,355 | 20.2x | 4.8x | 21.1 | 22 | 0.3 |
| Zydus Lifesciences Ltd. | 1,06,823 | 27,148 | 5,026 | 21.2x | 4x | 21.1 | 26.1 | 0.13 |
| Dr. Reddy's Laboratories Ltd. | 1,06,133 | 33,700 | 4,144 | 25.3x | 2.8x | 18.6 | 23.3 | 0.14 |